NCT04331093View on ClinicalTrials.gov

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Acral Melanoma
Interventions
DRUG

SHR-1210+Apatinib

"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"

Trial Locations (1)

130021

RECRUITING

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Di Wu

OTHER